Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 6, 2012, Pages 310-318

  Gaspar, Maria Manuela ^a,b   Radomska, Anna ^a,c   Gobbo, Oliviero L ^a   Bakowsky, Udo ^d   Radomski, Marek W ^a   Ehrhardt, Carsten ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

doxorubicin; drug targeting; intratracheal nebulization; large cell lung cancer; pulmonary drug delivery

Indexed keywords

DOXORUBICIN; LIPOSOME; TRANSFERRIN;

AEROSOL; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; FEMALE; LUNG ALVEOLUS CELL; LUNG CANCER; LUNG CARCINOGENESIS; MACROPHAGE; NONHUMAN; RAT; SURVIVAL TIME;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; LIPOSOMES; LUNG NEOPLASMS; NEBULIZERS AND VAPORIZERS; POLYETHYLENE GLYCOLS; RATS; RATS, NUDE; SURVIVAL RATE; TRANSFERRIN;

EID: 84870415226     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0928     Document Type: Article

References (39)

1. Jemal A, Thun MJ, Ries LAG, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, and Edwards BK: Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Nat Cancer Inst. ;23:1672-1694.
2. Gagnadoux F, Hureaux J, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, and Lemarie E: Aerosolized chemotherapy. J Aerosol Med Pulm Drug Deliv. ;21:61-70.
3. Maruyama K: Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev. 2011;63:161-169.
4. Torchilin V: Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev. 2011;63:131-135.
5. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, and Bally MB: The liposomal formulation of doxorubicin. In: Duzgunes N (ed.). Methods in Enzymology. Elsevier, San Diego, CA; pp. 71-97, 2005.
6. Menna P, Salvatorelli E, Gianni L, and Minotti G: Anthracycline cardiotoxicity. In: Krohn K (ed.). Anthracycline Chemistry and Biology II: Mode of Action, Clinical Aspects and New Drugs. Springer, Berlin; pp. 21-44, 2008.
7. Gabizon AA, Shmeeda H, and Zalipsky S: Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2006;16:175-183.
8. Kurmi BD, Kayat J, Gajbhiye V, Tekade RK, and Jain NK: Micro and nanocarrier-mediated lung targeting. Exp Opin Drug Deliv. 2010;7:781-794.
9. Doddoli C, Ghez O, Barlesi F, D'journo B, Robitail S, Thomas P, and Clerc T: In vitro and in vivo methotrexate disposition in alveolar macrophages: Comparison of pharmacokinetic parameters of two formulations. Int J Pharm. 2005;297: 180-189.
10. Bakowsky H, Richter T, Kneuer C, Hoekstra D, Rothe U, Ehrhardt C, and Bakowsky U: Adhesion characteristics and stability assessment of lectin-modified liposomes for sitespecific drug delivery. Biochim Biophys Acta Biomembr. ;778:242-249.
11. Widera A, Norouziyan F, and Shen WC: Mechanisms of TfR-mediated transcytosis and sorting in epithelial cells and applications toward drug delivery. Adv Drug Deliv Rev.;11:1439-1466.
12. Derycke AS, and de Witte PA: Transferrin-mediated targeting of hypericin embedded in sterically stabilized PEGliposomes. Int J Oncol. 2002;1:181-187.
13. Anabousi S, Bakowsky U, Schneider M, Huwer H, Lehr CM, and Ehrhardt C: In vitro assessment of transferrin-conjugated liposomes as drug delivery systems for the inhalation therapy of lung cancer. Eur J Pharm Sci. 2006;29:367-374.
14. Suzuki R, Takizawa T, Kuwata Y, Mutoh M, Ishiguro N, Utoguchi N, Shinohara A, Eriguchi M, Yanagie H, and Maruyama K: Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG-liposome. Int J Pharm. ;1-2:143-150.
15. Daniels TR, Delgado T, Rodriguez JA, Helguera G, and Penichet ML: The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121:144-158
16. Daniels TR, Delgado T, Helguera G, and Penichet ML: The transferrin receptor part II: Targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 2006;121:159-176.
17. Patton JS, Brain JD, Davies LA, Fiegel J, Gumbleton M, Kim KJ, Sakagami M, Vanbever R, and Ehrhardt C: The particle has landed - discerning the fate of inhaled pharmaceuticals. J Aerosol Med Pulm Drug Deliv. 2010;23:S71-S87.
18. Gaspar M, Bakowsky U, and Ehrhardt C: Inhaled liposomes - current strategies and future challenges. J Biomed Nanotechnol. 2008;4:245-257.
19. Gaspar MM, Gobbo O, and Ehrhardt C: Generation of liposome aerosols with the Aeroneb Pro and the AeroProbe nebulisers. J Liposome Res. 2010;20:55-61.
20. Selting K, Essman S, Reinero C, Branson KR, Henry CJ, Owen N, Guntur VP, Waldrep JC, Kim DY, and Dhand R: Targeted combined aerosol chemotherapy in dogs and radiologic toxicity grading. J Aerosol Med Pulm Drug Deliv. ;24:43-48.
21. Selting K, Waldrep JC, Reinero C, Branson K, Gustafson D, Kim DY, Henry C, Owen N, Madsen R, and Dhand R: Feasibility and safety of targeted cisplatin delivery to a select lung lobe in dogs via the AeroProbe/intracorporeal nebulization catheter. J Aerosol Med Pulm Drug Deliv. ;3:255-268.
22. Anabousi S, Laue M, Lehr CM, Bakowsky U, and Ehrhardt C: Assessing transferrin modification of liposomes by atomic force microscopy and transmission electron microscopy. Eur J Pharm Biopharm. 2005;60:295-303.
23. Stewart JC: Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104: 10-14.
24. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, and Kiwada H: Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein- mediated drug resistant tumor cells. Int J Pharm. 2007;1-2:94-102.
25. Li X M, Ding LY, Xu YL, Wang YL, and Ping QN: Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. Int J Pharm. 2009;1-2:116-123.
26. Fritze A, Hens F., Kimpfler A, Schubert R, and Peschka-Suss R: Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochim Biophys Acta Biomembr. 2006;10:1633-1640.
27. Bakowsky U, Rettig W, Bendas G, Vogel J, Bakowsky H, Harnagea C, and Rothe U: Characterization of the interactions between various hexadecylmannoside-phospholipid model membranes with the lectin Concanavalin A. Phys Chem Chem Phys. 2000;2:4609-4614.
28. Howard RB, Mullen JB, Pagura ME, and Johnston MR: Characterization of a highly metastatic, orthotopic lung cancer model in the nude rat. Clin Exp Metastasis. :17:157-162.
29. Yi D, and Wiedmann TS: Inhalation adjuvant therapy for lung cancer. J Aerosol Med Pulm Drug Deliv. 2010;23: 181-187.
30. Roa WH, Azarmi S, Al-Hallak MH, Finlay WH, Magliocco AM, and Lobenberg R: Inhalable nanoparticles, a noninvasive approach to treat lung cancer in a mouse model. J Control Release. 2011;150:149-155.
31. Verschraegen CF, Gilbert BE, Huaringa AJ, Newman R, Harris N, Leyva FJ, Keus L, Campbell K, Nelson-Taylor T, and Knight V: Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs. Ann N Y Acad Sci. 2000;922:352-354.
32. Garbuzenko OB, Saad M, Betigeri S, Zhang M, Vetcher AA, Soldatenkov VA, Reimer DC, Pozharov VP, and Minko T: Intratracheal versus intravenous liposomal delivery of siRNA, antisense oligonucleotides and anticancer drug. Pharm Res. 2009;26:382-394.
33. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, and Minko T: Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci USA. ;107:10737-10742.
34. Azarmi S, Roa WH, and Lobenberg R: Targeted delivery of nanoparticles for the treatment of lung diseases. Adv Drug Deliv Rev. 2008;60:863-875.
35. Anabousi S, Kleemann E, Bakowsky U, Kissel T, Schmehl T, Gessler T, Seeger W, Lehr CM, and Ehrhardt C: Effect of PEGylation on the stability of liposomes during nebulisation and in lung surfactant. J Nanosci Nanotechnol. 2006;6:3010-3016.
36. Torchilin VP: Recent advances with liposomes as pharmaceutical carriers. Nature Rev Drug Discovery. 2005;2: 145-160.
37. Lai SK, Wang YY, and Hanes J: Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv Drug Deliv Res. 2009:61:158-171.
38. Salomon JJ, and Ehrhardt C: Nanoparticles attenuate Pglycoprotein/MDR1 function in A549 human alveolar epithelial cells. Eur J Pharm Biopharm. 2011;77:392-397.
39. Al-Hallak KM, Azarmi S, Anwar-Mohamed A, Roa WH, and Lobenberg R: Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy Eur J Pharm Biopharm. ;76:112-119.